Next Generation Intratumoral Technology Targets Diffuse Intrinsic Pontine Glioma

Investigational New Drug Enabling Studies are Underway with Planned Clinical Trial to Begin Late 2026

FORT WORTH, Texas, Dec. 11, 2025 — NanOlogy, LLC, a private clinical-stage oncology company, is pleased to announce its drug development program aimed at transforming the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive highly lethal pediatric brainstem tumor. The company is developing Large Surface Area Microparticle (LSAM) Cisplatin for stereotactic intratumoral (IT) administration in this initial indication.

Plans for Pediatric Clinical Trials

NanOlogy is completing Investigational New Drug (IND) enabling studies required by the U.S. Food and Drug Administration (FDA). Upon completion of these studies, the company plans to submit an IND application for LSAM-Cisplatin to treat malignant neoplasms of the brain including DIPG. Subject to FDA allowance to proceed, NanOlogy aims to initiate a clinical trial in late 2026 to evaluate the safety and response of stereotactic IT administration of LSAM-Cisplatin in children diagnosed with DIPG. According to DIPG.org, DIPG afflicts 150 – 300 children annually in the United States, with median survival of less than one year. Current treatments, like radiation therapy, may delay progression but almost always fail to deliver long term survival. NanOlogy is also assessing future opportunities to extend the use of LSAM-Cisplatin to treat other brain and solid tumors.

The Promise of LSAM-Cisplatin in DIPG

In laboratory research studies, cisplatin has been shown to kill DIPG tumors by binding to DNA and disrupting cell replication, leading to cell death. Unfortunately, current systemically administered cisplatin formulations are associated with numerous severe side effects throughout the body. In addition, cisplatin does not cross the blood brain barrier well, limiting its efficacy in brain tumors, making systemically administered cisplatin a suboptimal treatment for DIPG.

“We believe NanOlogy’s innovative LSAM-Cisplatin investigational drug designed for intratumoral administration can overcome the limitations of current treatment options with highly targeted delivery of drug into the tumor, continuous drug release, and minimal systemic toxicity,” said H. Paul Dorman, founder and chairman of NanOlogy. “Advancements in minimally invasive surgical procedures and imaging now allow local delivery of LSAMs to solid tumors virtually anywhere in the body, including the brain. We are excited to advance IT LSAM-Cisplatin for DIPG and explore the promise it may hold for children and families facing this devastating disease.”

About NanOlogy

NanOlogy, LLC (www.nanology.us) is a private clinical-stage oncology company developing treatments for solid tumors using drugs optimized for intratumoral delivery designed to improve response with minimal to no systemic toxicity. Enabled by the CritiTech Particle Engineering Solutions’ Purcision™ technology platform, NanOlogy produces Large Surface Area Microparticles (LSAMs) of pure drug for direct local delivery overcoming issues of systemic toxicity and tumor bioavailability. NanOlogy clinical programs have advanced LSAM investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. Feasibility of the Purcision™ platform has been established in taxanes, platins, tyrosine kinase inhibitors, poly (ADP-ribose) polymerase inhibitors, and other agents. The investigational drugs are covered by composition of matter patents issued in the United States and other major jurisdictions worldwide, including Canada, Europe, Japan, China, South Korea, Australia, and India, which form the foundation of an extensive intellectual property portfolio of over 100 issued patents protecting NanOlogy investigational drugs, formulations, methods, and technology.

Media Contact

Marc Iacobucci
[email protected] 
1-817-916-2287

SOURCE NanOlogy, LLC

TORRANCE, Calif., Dec. 11, 2025 — K2 Space, the California-based developer of large, high-power satellite platforms, today announced a $250 million Series C at a $3 billion valuation, accelerating delivery of a new generation of spacecraft built for the heavy-lift era. The financing follows $500 million in signed contracts across commercial and U.S. government customers and is led by Redpoint, with participation from accounts advised by T. Rowe Price Associates, Inc., and from Hedosophia, Altimeter, Lightspeed, and Alpine Space Ventures.

K2 was founded in 2022 on a single thesis: the rise of launch vehicles like Falcon 9, Starship and New Glenn will make it possible to build an entirely new category of satellite. Satellites that are larger, higher power and more reliable; that can be deployed in any orbit – LEO, MEO, and GEO – rather than confined to one. These capabilities will become increasingly important as critical applications like communications and compute get pushed from terrestrial networks to space.

“Space is becoming one of the most strategically important technology sectors, and it’s attracting investment because the underlying demand is real and accelerating,” said Elliot Geidt, Partner at Redpoint. “What stands out about K2 is how much core hardware they’ve built themselves. They’re not assembling a satellite; they’re redefining the architecture needed for the next decade of missions.”

“K2 is tackling one of the biggest limitations in the space economy: meaningful increases in power and scale,” said T. Rowe Price investment analyst Jason Leblang. “Their approach isn’t incremental. They’re rethinking satellite design from the ground up, and the result is a platform that can support entirely new classes of missions. That’s why we’re confident in the team and the trajectory.”

Building the technical base for the next class of missions

K2’s first two years were spent solving what the commercial supply chain hadn’t: the foundational subsystems required for large, high-power, highly resilient spacecraft. The team designed the highest power hall-effect thruster ever flown – 4x more powerful than anything that’s flown to-date; large solar arrays, designed to reliably generate maximum power; a radiation-tolerant avionics suite built to survive high radiation environments; massive reaction wheels; high voltage power systems; and much more.

Those designs weren’t just theoretical. Earlier this year, K2 flew its hardware as part of a hosted-payload mission that validated the flight computer, reaction wheel, and avionics stack in space, de-risking the core of the platform ahead of full-system integration.

“Each subsystem had to be built to a new performance class,” said Neel Kunjur, Co-Founder and CTO. “That engineering forms the basis of our high-power ‘Mega’ line, and it’s why we can take customers beyond the limits of the small-satellite era.”

Four months to launch: The Mega Class satellite

In March 2026, K2 will launch GRAVITAS, the company’s first production of its “Mega Class” satellite. While small relative to what K2 is designing next, the Mega Class satellite is on par with the largest satellites that have ever been produced. Mega is designed to fly on today’s workhorse rockets, including Falcon 9, Vulcan, and Ariane 6, while delivering approximately 10× the power of other satellites in its class. Built from the outset for multi-orbit operations, Mega is hardened for some of the harshest environments in the solar system and engineered with redundancy and reliability techniques historically reserved for human-rated vehicles like Dragon and the Space Shuttle.

The mission represents K2’s first spaceflight of the fully integrated, in-house system and will open a comprehensive test campaign:

• The first in-space firing of a 20 kW Hall-effect thruster – roughly 4× more powerful than anything flown to date.
• The first deployment of the large twin 10 kW solar arrays on the platform (20kW total).
• The first on-orbit exercise of K2’s high-voltage power system paired with radiation-tolerant avionics.

“GRAVITAS brings our full stack together for the first time,” said Karan Kunjur, Co-Founder and CEO. “We are validating the architecture in space, from high-voltage power and large solar arrays to our guidance and control algorithms, and a 20 kW Hall thruster, and we will scale based on measured performance.”

“We pushed our propulsion hard on the ground and were thrilled to hot-fire at the full 20 kW,” added Rafael Martinez, who leads K2’s high-power electric propulsion program. “Now we’re eager to characterize the thruster’s performance in space.”

From first flight to full-rate production

Following Mega’s launch, K2 will ramp manufacturing at its 180,000 –sq.-ft. Torrance factory, sized to produce 100 high-power satellites per year. That capacity will be needed as K2 starts delivering against $500 million in signed commercial and government contracts. Customers include large operators like SES, who recently announced plans to partner with K2 on its future MEO network. Multiple launches across 2026-2027 are planned, with operational commercial and national security constellations beginning deployment starting in 2028.

“K2 is bringing something brand new to the space industrial base: low cost, high power satellites produced at speed and scale,” said Dr. John Plumb, Head of Strategy at K2. “Our innovative approach will enable entire satellite constellations of exquisite payloads – something unimaginable due to its prohibitive cost before K2 showed up.”

Next up: Giga, built for super-heavy lift

With Mega establishing the production baseline, K2 will next unveil plans for designing Giga: its large-class spacecraft designed specifically for Starship and New Glenn. Giga will deliver 100kW of power per satellite, enabling missions that previously only existed in science fiction:

• AI scale compute on orbit
• High-throughput networks spanning orbits – and planets
• Mass-produced giant telescopes to vastly expand scientific return from across the solar system and beyond

“Our north star is simple,” said Karan Kunjur. “If we build these platforms well, we get to ask new questions about what’s possible in orbit.”

Media Contact:
[email protected]

About K2 Space
At K2 Space, we’re Building Bigger.

K2 is building the largest and highest-power satellites ever flown, unlocking performance levels previously out of reach across every orbit.

By scaling capability and production, K2 delivers systems ready for the most demanding missions – from national security and global communications to deep-space research – with reliable performance wherever they operate.

Founded by former SpaceX engineers, K2 Space has raised more than $450M from leading investors including Altimeter Capital, Redpoint, accounts advised by T. Rowe Price Associates, Inc., Lightspeed Venture Partners, and Alpine Space Ventures.

SOURCE K2 Space

MIAMI, Dec. 11, 2025 — In the high-stakes world of professional sports, “innovation” is often reduced to buying better equipment or signing more expensive players. But for Ilya Movshovich, Managing Partner at Digital Athlete Ventures and owner of Cobh Ramblers FC, true innovation isn’t about spending more, it’s about seeing differently.

While the industry largely relies on tradition and intuition, Ilya Movshovich is applying the rigorous, data-driven disciplines of Venture Capital to the unpredictable world of football. The result is a new blueprint for ownership: one that views a sports club not as a vanity asset, but as a scalable technology platform.

The Thesis: Arbitrage in the Locker Room

“The sports industry is filled with inefficiencies,” says Ilya Movshovich. “And where there is inefficiency, there is opportunity.”

At Digital Athlete Ventures, the core philosophy is identifying value where others see noise. Ilya Movshovich has taken this VC thesis, normally reserved for Silicon Valley startups, and applied it directly to the operations of Cobh Ramblers FC.

The strategy is distinct: treat the club as a high-growth ecosystem. While traditional owners obsess over the final score, Ilya Movshovich obsesses over the leading indicators, the systemic, often invisible metrics that predict long term success. This is an innovative approach to “asset management” that prioritizes sustainable infrastructure over short term fixes.

Innovative Approaches: Measuring the “Unmeasurable”

Where most clubs look at physical data (speed, distance, strength), Ilya Movshovich drives results by looking for the “hidden” data points that actually dictate the game.

1. Cognitive Analytics & The Digital Mind The next frontier in sports isn’t physical; it’s mental. However, the industry has historically treated mental performance as a soft skill, impossible to measure. Ilya Movshovich disagreed.

The Innovation: By integrating advanced cognitive assessment tools into the club’s regimen, Ilya Movshovich is digitizing the mental game. The club creates profiles based on decision making speed, spatial awareness, and cognitive resilience under pressure.

The Strategic Edge: This allows the club to recruit and develop players based on their “processing power,” not just their athleticism. It is a market inefficiency that Ilya Movshovich is exploiting to build a squad that thinks faster than the opposition.

2. Vertical Integration of Talent In the tech world, controlling your supply chain is critical. In football, that “supply chain” is the Academy.

The Innovation: Rather than treating the youth system as a lottery, Ilya Movshovich utilizes data modeling to track developmental trajectories years in advance. This is “Talent R&D.” By investing heavily in the systems that produce players, the club reduces its reliance on the volatile transfer market. It’s a move away from the “buy talent” model to a “build talent” model, securing long term asset value.

3. The Club as a Platform Traditional thinking separates the “business” from the “team.” Ilya Movshovich integrates them. By treating the club as a digital media platform, Ilya Movshovich has unlocked new revenue streams through global digital engagement, rather than relying solely on local ticket sales.

The Innovation: This approach decouples revenue from match day results, creating a stable financial baseline that allows the club to take calculated risks on the pitch that other clubs cannot afford to take.

The “Digital Athlete” Vision

This convergence of strategy leads to what Ilya Movshovich defines as the “Digital Athlete”-a holistic view of the player where health, performance, and psychology are interconnected through data.

“We don’t guess,” Ilya Movshovich asserts. “In Venture Capital, you don’t invest based on a feeling; you invest based on the unit economics and the team’s capacity to execute. We run the club the same way. We use technology to de-risk our decisions.”

Conclusion: The Innovator’s Advantage

In an industry that is notoriously resistant to change, Ilya Movshovich is proving that the greatest competitive advantage is a willingness to break the mold. By bridging the gap between the boardroom of Digital Athlete Ventures and the dugout of Cobh Ramblers FC, Ilya Movshovich is doing more than just planning on winning games.

They are here to demonstrate that when you treat sports with the intellectual rigour of a tech venture, you find results in places where no one else is even looking.

About Digital Athlete Ventures (DAV)

Digital Athlete Ventures (DAV) is a sports and media investment firm that acquires majority stakes in sports teams across the globe.

Media Contact: mailto:  Ilya Movshovich, 1-408-806-0393, [email protected]

To Learn more visit: www.digitalathleteventures.vc

SOURCE Digital Athlete Ventures

Equity-backed commitment dramatically de-risks pivotal program, boosts licensing appeal, and strengthens commercialization readiness.

HUNTINGTON, N.Y., Dec. 11, 2025 — Sen-Jam Pharmaceutical, a clinical-stage biotechnology company pioneering novel anti-inflammatory combination therapeutics, today announced a transformative partnership with TASK Clinical, a global contract research organization (CRO). Under the agreement, TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity — an exceptionally rare commitment that significantly de-risks development, enhances investor confidence, and strengthens the program for global licensing opportunities.

This milestone follows Sen-Jam’s recent announcement appointing Rute Fernandes, a seasoned global life-sciences executive with leadership roles across Takeda, Shire, and Novartis, as Executive Advisor to accelerate commercialization pathways.

A Synergistic Partnership Network: TASK Clinical + KVK Tech

Sen-Jam now benefits from a vertically integrated development ecosystem:

• TASK Clinical providing clinical leadership and majority funding of Phase 3
• KVK Tech, Sen-Jam’s established corporate venture partner/CMO, driving formulation, CMC, and FDA submission readiness
• Rute Fernandes guiding global market expansion and commercialization strategy

KVK Tech has made significant progress in the formulation development and CMC work for SJP-001, including the manufacturing of GMP batches. Upon completion of the ongoing Phase 2 dose-ranging study, KVK Tech will finalize the FDA submission batches, enabling a rapid transition into Phase 3 and subsequent regulatory filing.

This powerful alignment ensures Sen-Jam is de-risked across clinical, manufacturing, operational, and commercial dimensions — a rare position for a company at this stage.

Quotes from Leadership

Jim Iversen, Co-Founder & CEO, Sen-Jam Pharmaceutical

“This partnership with TASK Clinical reflects a shared belief in the scientific and commercial potential of SJP-001. Having a global CRO take an equity position in our pivotal Phase 3 trial is a powerful signal to investors and future licensing partners. Combined with KVK Tech’s formulation and CMC execution and Rute’s commercial leadership, Sen-Jam is entering the strongest phase in its history.“

Johann de Bruyn, Chief Executive Officer, TASK Clinical

“We chose to invest directly in Sen-Jam and fund the majority of the Phase 3 program because we believe SJP-001 has the potential to be a first-in-category global therapy. It is uncommon for a CRO to assume an equity position in a pivotal trial, but Sen-Jam’s science, strategy, and team earned our confidence. We are proud to partner with Sen-Jam and look forward to executing a world-class Phase 3 study together.”

Rute Fernandes, Executive Advisor, Sen-Jam Pharmaceutical

“TASK Clinical’s commitment to fund the majority of Phase 3 is a powerful validation of Sen-Jam’s scientific foundation and strategic direction. I have rarely seen a CRO take such a substantial equity position in a sponsor’s pivotal program. The strength of this partnership, combined with the manufacturing readiness provided by KVK Tech, significantly de-risks SJP-001 for investors and accelerates our pathway to global licensing and commercialization. I am thrilled to help guide Sen-Jam in turning this momentum into widespread impact.“

SJP-001: A First-in-Category Opportunity

SJP-001 is Sen-Jam’s lead combination therapy designed to modulate the inflammatory cascade triggered by alcohol consumption — the underlying biological cause of next-day symptoms such as headache, malaise, nausea, and cognitive impairment. If approved, SJP-001 could become the first FDA-regulated hangover-prevention therapeutic, representing a first-in-category commercial opportunity in an underserved global market.

The Phase 2 trial, conducted by Cliantha Research in Toronto, Canada, was completed in November with data readout and final analysis expected Q1 2026.

Growing Visibility: Jackie Iversen’s TEDx Talk

Momentum continues to build through Co-Founder Jackie Iversen’s recent TEDx Talk “How Mastering Hangovers Reveals the Science of Longevity“, spotlighting the critical role of inflammation in human health and the urgent need for accessible, science-backed innovation. Her talk has broadened awareness of Sen-Jam’s mission, reinforcing the company’s leadership at the intersection of inflammation science and global health transformation.

A De-Risked, Licensing-Ready Therapeutics Company

Sen-Jam now represents one of the most attractive emerging assets in inflammation therapeutics, supported by:

• De-risked Phase 3 funding via TASK
• Manufacturing and regulatory readiness through KVK Tech
• Seasoned commercial leadership from Rute Fernandes
• Global thought leadership highlighted through TEDx
• A first-in-category therapeutic backed by robust scientific rationale

Together, these elements position Sen-Jam for accelerated investor engagement, strategic partnership development, and global licensing discussions.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is transforming the management of inflammation through novel, low-cost, combination therapeutics designed for safety, efficacy, and global accessibility. Its proprietary PAIR platform targets inflammatory cascades across acute and chronic conditions. Lead programs include SJP-001 for alcohol-induced inflammation and SJP-002C for viral respiratory symptoms. For more information, visit www.wefunder.com/senjam.

About TASK Clinical

TASK Clinical is a global contract research organization specializing in multi-site, late-phase clinical trials. With expertise spanning North America, Europe, and emerging markets, TASK delivers comprehensive development support and operational excellence to accelerate the approval and commercialization of innovative therapeutics.

About KVK Tech

KVK Tech is an FDA-approved pharmaceutical manufacturer specializing in formulation development, CMC execution, and large-scale commercial production. As Sen-Jam’s corporate venture partner, KVK Tech has led the formulation and CMC work for SJP-001 and will complete the FDA submission batches necessary for the upcoming Phase 3 program.

CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
781-913-1902
[email protected] 

SOURCE Sen-Jam Pharmaceutical

CHICAGO, Dec. 11, 2025 — Nurse Capital, a venture capital firm that invests in nurse-led startups, is pleased to announce a significant investment from its Fund I in RoddyMedical, Inc., a medical device innovator focused on developing products that enhance patient safety and improve staff effectiveness in clinical settings.

The Wauwatosa, WI-based startup’s flagship product, SecureMove-TLC^®, is a patented, wearable medical device designed to prevent medical tubing hazards that occur all too frequently in a hospital setting. The armband-style device secures and manages different types of medical tubes, lines and cords employed in patient care; and eliminates hazardous pulling and line/cord dislodgement during a patient’s therapy, transport, and movement. It can be worn for up to 30 days, and also provides nursing staff with more efficiency, convenience and time savings.

“Nurses don’t just see problems—they engineer solutions that work,” said Beth A. Brooks, PhD, RN, FACHE, Co-Founder of Nurse Capital. “Because nurses live the clinical realities day after day, their innovations are immediately usable and quickly adopted. SecureMove-TLC^® is exactly that kind of solution—designed from lived experience to reduce patient harm and improve workflow. RoddyMedical shows why investing in nurse-led innovation is both clinically smart and financially sound.”

One of the device’s key benefits is patient mobility. Getting patients up and moving during their hospital stay leads to earlier discharge, fewer hospital-acquired conditions, fewer readmissions, and significant hospital savings, noted RoddyMedical Founder and CEO Lindsey Roddy, RN, PhD(c). But it’s no easy task.

 “Therapy begins just hours after a major surgery, but is often inhibited by the number of tubes, lines, and cords attached to a patient in the ICU,” said Roddy. And those lines and cords can be dangerous. Recent studies have found that 19 million lines are pulled out every year from acute care patients, who can often be attached to up to 15 lines. Healthcare workers spend 64% of their time untangling and organizing lines when providing early mobility and therapy in the ICU. Healthcare facilities spend an additional $266 million each year replacing vascular access devices as a result of compromised lines and dislodgements. 

Roddy launched her startup in 2018 after she herself almost lost one of her patients in the ICU due to a medical tubing hazard. When assisting a patient getting out of bed after surgery for therapy, the line carrying the patient’s life support got caught and pulled out of his neck—an upsetting experience that drove her to find a better solution. Unable to find anything on the market that could have prevented this problem, Lindsey began to design a device that would prevent this from ever happening again. After several years in development, the startup introduced the SecureMove-TLC^® .

Currently, the device is being used in hospitals in six states including Mayo Clinic (Phoenix, AZ), Barnes Jewish (St. Louis, MO), and The Ohio State University Hospital, among others. It has also secured five global patents on its device.

“Nurse Capital is pleased to support nurse entrepreneurs like Lindsey Roddy as they bring their unique expertise to innovative solutions which better serve their patients,” said Nurse Capital Co-founder Marla J. Weston, PhD, RN.

RoddyMedical is now raising $5 million in Series A funding to expand its manufacturing capacity and market penetration.

About Nurse Capital

Nurse Capital is a nurse-founded and managed venture capital fund based in Chicago that makes early-stage investments in nurse entrepreneurs leading high-growth-potential businesses that are transforming the future of healthcare. Learn more at https://nursecapital.net/. 

About RoddyMedical, Inc.

RoddyMedical is a women founded and operated, Wisconsin based C-Corp, headquartered in Wauwatosa, WI, focused on developing innovative medical devices that improve clinical safety & patient outcomes. Its founding team has complementary experience in hospital-based patient care, medical device product design and development, manufacturing, and marketing. For more information, visit www.roddymedical.com.

SOURCE Nurse Capital

BASEL, Switzerland, Dec. 11, 2025 –Allegria Therapeutics (ALLEGRIA), a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced today the successful completion of a USD 5.1 million seed extension financing.

The financing round was led by ALK Abelló, with participation of HighLight Capital (HLC), Lichtsteiner Foundation and co-founding investor Forty51 Ventures.

The investment sets the stage for accelerated growth and value creation for ALLEGRIA. The funds will be used to progress its lead program towards pre-clinical candidates in support of nomination its first clinical candidate, while at the same time meaningfully advancing its discovery-stage programs.

ALLEGRIA was founded in 2023. Since its inception, the company has established a highly experienced specialist core team and advisory board. ALLEGRIA is progressing a differentiated portfolio of proprietary therapeutic approaches and targets to selectively modulate mast cells. By leveraging its unique insights and strategy, it has identified differentiated molecules that have great promise for the development of transformative therapies with first-in-class and best-in-disease potential for the treatment of patients with allergies and related inflammatory conditions.

“Precision approaches offer the ability to target defined cell types and pathways to disrupt the pathogenic biology driving disease with optimal efficacy and safety” says Maria van Dongen, Ph.D., Co-founder and CEO. “By identifying the relevant pathways and targets in uncontrolled mast cell activation, and leveraging our extensive experience in drug development, we aim to bring more and better options to patients across numerous allergic and inflammatory diseases. The current financing round importantly supports us in that journey.”

ALK-Abelló (ALK), a global specialty pharmaceutical company focused on allergy and allergic asthma, is providing ALLEGRIA with a strong partner in the allergy space.

Peter Sejer Andersen, Ph.D., Senior Vice President of Global Research and Drug Discovery at ALK says: “Every year hundreds of millions are impacted by allergy, affecting their daily lives and potentially causing life threatening situations. Building on our strong heritage, our mission is to help five million people every year by 2030 through innovative and more effective solutions.” He continues: “We have followed ALLEGRIA’s development and have been repeatedly impressed with their advancements and team, as well as their highly original strategy for novel treatments for allergic disorders. Our investment in ALLEGRIA is well aligned with our Allergy+ strategy.”

Further, Henry He, Chief Investment Officer at HLC notes: “We are excited to be able to invest in ALLEGRIA, as the company is an excellent example of first-in-class therapeutic innovations that could significantly reduce the burden of several chronic diseases. Growing scientific and clinical insight shows that mast cells play an important role in a range of human pathologies. We look forward to supporting the further development of ALLEGRIA.“

ALLEGRIA collaborates with world leading partners in fundamental mast-cell biology, drug discovery and preclinical drug evaluation including Prof. Dr. Martin Metz, Managing Director of the Institute for Allergology at Berlin’s Charité and Ap. Prof. Dr. Philipp Starkl, Principal Investigator at the Medical University of Vienna.

Following this seed extension round, Dr. Peter Sejer Andersen has joined ALLEGRIA’s Board as non-executive director, thereby further strengthening the company’s leadership team.

ALLEGRIA is based in Basel, Switzerland, a broadly recognized hotspot for biotech and pharma.

ABOUT ALLEGRIA THERAPEUTICS

Allegria Therapeutics was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches and biological targets to selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases. For more information, please visit allegriatx.com.

ABOUT FORTY51 VENTURES

Forty51 Ventures is a venture capital firm with its core strategy focused on company formation in Biotech. Forty51 Ventures leads and co-leads early financing rounds of its growing portfolio which includes Pharma and Large Biotech spin-outs. www.forty51ventures.com

ABOUT ALK-ABELLÓ

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen.  Find more information at www.alk.net.

ABOUT HIGHLIGHT CAPITAL

HLC is a private investment firm dedicated to creating long-term value through promoting technology innovations. Leveraging deep expertise in chemical, biological and materials sciences and proprietary industry research, the firm invests in companies that enhance manufacturing efficiency and improve human wellness. HLC currently manages over USD 3.8 billion across key financial hubs, including Tokyo, Shanghai, Hong Kong and Boston. www.hlcfund.com 

ABOUT LICHTSTEINER FOUNDATION

The Lichtsteiner Foundation supports early-stage startups in the fields of medical technology, life science, mental health, public health, and wellbeing, to help pioneers bring their inventions to life. The foundation focuses on impact investing by providing funding in the form of equity. Check the website for more information: lichtsteinerfoundation.org or follow on LinkedIn.

Logo:- https://mma.prnewswire.com/media/2842790/Allegria_Therapeutics_Logo.jpg

SOURCE Allegria Therapeutics AG

Related Links

https://mma.prnewswire.com/media/2842790/ALLEGRIA_THERAPEUTICS.jpg
https://mma.prnewswire.com/media/2842790/ALLEGRIA_THERAPEUTICS.jpg

PHILADELPHIA, Dec. 11, 2025 — Ritten, a leading AI-powered system of record for behavioral health providers, today announced a $35 million USD Series B funding round led by Five Elms Capital with participation from existing investors Threshold Ventures, 8VC, Bienville Capital, and others. This investment will support Ritten’s expansion across mental health and addiction treatment providers spanning all levels of care.

“Behavioral health providers do extraordinary work in some of the most demanding care environments, and our team has always been dedicated to giving them the next generation of tools that reduce friction and improve care. Five Elms immediately understood our mission and approach,” said Noah Whitehead, CEO of Ritten. “This partnership with Five Elms will allow us to advance our AI-first roadmap, continue supporting clinicians and staff, and scale solutions that meet the nuanced requirements of behavioral health.”

Since its founding in 2020, Ritten has been dedicated to enabling behavioral health practitioners to deliver the highest quality care. By unifying electronic medical records, customer relationship management, and revenue cycle management into one modern AI-enabled platform, Ritten streamlines the entire patient and clinician journey, from referrals and admissions to scheduling, charting, compliance, and billing across both outpatient and residential settings. Ritten’s technology reduces toil and burnout for staff and drives operational efficiencies and growth for customer facilities.

Ryan Mandl, Partner at Five Elms, commented on the investment, “Ritten is revolutionizing a space that has long been underserved by fragmented, outdated technology. Their platform unifies the critical systems that practices need to grow, operate efficiently, and deliver high-quality treatment, enhanced by AI to meaningfully reduce complexity for care teams. We’re thrilled to be part of the next phase of Ritten’s growth.”

In addition to the acceleration of growth across the behavioral health space, Five Elms Capital’s investment in Ritten will contribute to further advancement of best-in-class AI capabilities for both practitioners and revenue cycle management. The company plans to continue to integrate AI-powered workflows throughout the platform, expand and mature their customer support offerings, and grow enterprise capabilities to meet the evolving needs of treatment organizations large and small.

About Ritten

Ritten is a unified behavioral health practice management platform purpose-built for substance use disorder and mental health treatment providers. The platform combines a robust EHR, integrated CRM, and comprehensive RCM into a single system of record, helping organizations streamline operations, remain compliant, and deliver higher-quality care. Founded in 2020 and headquartered in Philadelphia, Ritten serves treatment centers across the U.S., spanning single-site providers to multi-state enterprise groups. For more information, please visit ritten.io.

About Five Elms Capital

Five Elms Capital is a growth investor in software businesses that users love, providing capital and resources to help companies accelerate growth and further cement their role as industry leaders.

With over $3 billion in assets under management and a team of over 80 professionals, Five Elms has invested in more than 70 software platforms worldwide. Beyond providing capital, Five Elms delivers strategic and operational expertise, focused on executing initiatives that move the needle on growth, retention, product, and AI to set companies up for long-term success. For more information, visit fiveelms.com.

SOURCE Five Elms Capital

Now valued at $5.5 billion, Harness will use the new capital to advance Harness AI and accelerate platform expansion and global GTM momentum.

SAN FRANCISCO, Dec. 11, 2025 — Harness, the AI Software Delivery Platform company, today announced a $240 million Series E financing round. The financing round is comprised of a $200 million investment led by Goldman Sachs Alternatives and a planned $40 million tender offer with participation from IVP, Menlo Ventures, and Unusual Ventures. This investment values Harness at $5.5 billion and reflects the accelerating demand for a unified, AI-native platform for software delivery.

While AI is transforming how software is written, that work represents only the beginning of the engineering lifecycle. Most teams spend just 30–40% of their time writing and iterating on code; the remaining 60–70% goes to the “outer loop” — testing, deployments, security, compliance, and optimization. These workflows are deeply interconnected and remain highly manual, creating friction that slows velocity. Harness is bringing AI and automation to this outer loop, turning the most complex and time-consuming parts of software delivery into intelligent, streamlined processes.

Now, AI is amplifying the pressure exponentially. Code volume is accelerating — in many cases by 4x — and every line must still be tested, secured, deployed, and maintained. The surge of AI-generated code is further widening the gap between rapid development and the safe, reliable delivery of software. Organizations increasingly need intelligence and automation that can manage the entire after-code lifecycle — and Harness provides the platform that brings these AI capabilities together.

“The next frontier for AI in software engineering is applying intelligence to the delivery process — testing, verification, deployments, governance, and everything that happens after code is written,” said Jyoti Bansal, cofounder and CEO of Harness. “Our customers are moving faster than ever with AI, but the delivery process is where complexity and risk pile up. Harness is leading the way in bringing clarity, automation, and control to this part of the lifecycle so teams can ship software quickly, safely, and reliably at scale.”

Harness: The AI Software Delivery Platform

The new investment will help accelerate the evolution of Harness AI, a unified system purpose-built for everything after code. Harness AI is designed to eliminate the downstream bottlenecks that slow down engineering velocity. By combining specialized AI agents, deep organizational context, and reliable orchestration, the platform turns software delivery workflows into an intelligent system that learns, adapts, and acts on behalf of engineering teams.

Harness AI is built with three foundational layers that bring intelligent automation to the software development lifecycle:

• AI Agents purpose-built for software delivery: A library of focused agents that perform delivery, testing, verification, security, governance, and operational tasks — removing the manual coordination traditionally required across teams and tools.
• The Software Delivery Knowledge Graph: A unified context model mapping code changes, services, deployments, tests, environments, incidents, policies, and cost signals. This layer makes AI precise, trustworthy, and aligned to each customer’s architecture and workflows.
• Enterprise-grade orchestration engine: A reliable execution engine that transforms AI-driven insight into consistent automation across pipelines and environments, ensuring decisions are evaluated and implemented safely and predictably.

With deep organization-specific context, every action taken by Harness AI is precise and aligned to each customer’s architecture and workflows. Issues are identified earlier, evaluated with full context, and resolved before they reach production. Teams ship faster, not because they accept more risk, but because the platform absorbs the complexity on their behalf.

These capabilities are already driving measurable outcomes for Harness’s 1,000+ enterprise customers:

• United Airlines accelerated deployment times by 75% and migrated 80% of workloads to the cloud.
• Morningstar modernized its CI/CD ecosystem, achieving 5x faster builds, consolidating 36,000 pipelines to 50 templates, and transitioning from weeks-long releases to daily deployments.
• Keller Williams increased deployment frequency by 6x and saved 3 weeks in every release cycle.
• National Australia Bank (NAB) reduced build times by 67% and improved troubleshooting efficiency by 85%.

“AI has shifted the bottleneck from writing code to delivering it, and Harness is solving that problem at enterprise scale,” said Beat Cabiallavetta, Partner at Goldman Sachs Alternatives. “Their unified platform — combining AI, context, governance, and security — is resonating with organizations redesigning their engineering systems for the AI era. Harness is helping shape the future of modern software delivery.”

Harness Momentum

This next era of software delivery is already taking shape across Harness’s customer base, reflected in the scale, adoption, and global momentum Harness has built over the past year:

• ARR Growth: On track to exceed $250M ARR in 2025, with 50%+ YoY growth.
• Platform Scale: Powered 128M deployments, 81M builds, 1.2T API calls protected, and $1.9B in cloud spend optimization for customers over the last 12 months.
• Enterprise Adoption: Trusted by 1,000+ enterprise engineering teams across North America, EMEA, and APAC.
• Global Expansion: Grown to a 1,200+ employee team across 14 offices worldwide.
• Industry Recognition: Named to leading innovation and workplace lists, including the Forbes Cloud 100, Fast Company’s Best Workplaces for Innovators, and Inc. Magazine Power Partners.

Harness will use the Series E funding to accelerate platform innovation, expand its global footprint, and advance its vision for a world where the process of getting code to production is automated, secure, resilient, and governed by design.

To learn more about Harness and the future of AI software delivery, visit harness.io.

About Harness
Harness is the AI DevOps Platform™ company, enabling engineering teams to build, test, and deliver software faster and more securely. Powered by Harness AI and the Software Delivery Knowledge Graph, the platform brings intelligent automation to every stage of the software delivery lifecycle after code—removing toil and freeing developers from manual, repetitive work. Companies like United Airlines and Choice Hotels use Harness to accelerate releases by up to 75%, cut cloud costs by 60%, and achieve 10x efficiency across DevOps. Based in San Francisco, Harness is backed by Menlo Ventures, IVP, Unusual Ventures, and Citi Ventures.

About Goldman Sachs Alternatives 
Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $500 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.

The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.

The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors and individuals. Goldman Sachs has approximately $3.5 trillion in assets under supervision globally as of September 30, 2025.

Follow us on LinkedIn.

SOURCE Harness

BOSTON, Dec. 11, 2025 — OnCorps AI, a leading agentic AI platform for fund operations, has secured $55 million in growth capital from Long Ridge Equity Partners, a growth equity firm with deep experience in financial and business technology. The company will use the capital to accelerate product innovation, expand go-to-market teams, and scale infrastructure to support its rapidly growing customer base.

Founded in 2011, OnCorps AI delivers intelligent exception resolution for fund operations, primarily serving asset managers and fund administrators. Beyond detecting discrepancies in trade reconciliations and fund documentation, the platform autonomously investigates root causes, provides recommendations for issue resolution, and learns from patterns to prevent future breaks. 

“We’ve been running complex AI solutions in production for the world’s largest asset managers for several years, giving us a meaningful advantage in delivering tangible returns from AI,” said Bob Suh, Founder of OnCorps AI. “Every day, our systems close exceptions, reconcile trades, and oversee trillions in assets with high accuracy and low error rates. With Long Ridge’s investment, we can expand these capabilities across the broader industry.”

OnCorps’ specialized AI agents are trained on millions of real-world data discrepancies and exceptions across trade processing, fund accounting, and reporting workflows. This deep domain training, coupled with continuous learning from production environments, enables OnCorps to achieve accuracy rates and exception resolution times that general-purpose automation tools cannot match. 

Asset management operating margins have fallen in recent years, driven by surging transaction volumes, heightened regulatory requirements, and persistent fee compression. In an effort to drive efficiency, PIMCO, GMO, and other leading institutions – representing $13 trillion in assets – are turning to OnCorps to reduce manual effort and streamline their fund operations. 

In connection with the investment, Long Ridge Managing Partners Jim Brown and Kevin Bhatt will join the OnCorps AI Board of Directors.

“OnCorps AI has built the market-leading AI platform for fund operations,” said Jim Brown. “Their production-ready agents are trained on domain-specific data and workflows, delivering immediate operational value. We are excited to partner with Bob and the OnCorps team as they scale the business.”

The funding will enable OnCorps to expand into adjacent capital markets workflows where clients face similar challenges, including cash management, regulatory reporting, and complex trade processing.

Today, OnCorps provides customers with:

• AI-First Reconciliations: Leverages deep research agents to accelerate reconciliation processes by automating data matching, review, and investigation, reducing manual effort and cycle time.
• AI-First Reporting Reviews: Enables asset managers and service providers to automate and streamline the review of quarterly, semi-annual and annual financial reports, improving accuracy, consistency, and efficiency.

TD Securities served as OnCorps’ lead financial advisor. Altman Solon was the consulting partner. Goodwin Procter acted as legal counsel to Long Ridge, and Sidley Austin LLP served as legal counsel to OnCorps.

About OnCorps AI

OnCorps AI is a leading agentic AI platform for fund operations. The company delivers intelligent exception resolution for trade reconciliations, fund reporting, and related operational workflows. By optimizing the investigation and resolution of complex exceptions, OnCorps drives efficiency and risk reduction for asset managers and fund administrators. For more information, visit www.oncorps.ai.

About Long Ridge Equity Partners

Founded in 2007, Long Ridge Equity Partners is a private investment firm focused on the financial and business technology sectors. Leveraging deep sector knowledge and an extensive network of industry resources, Long Ridge serves as a value-added partner to high-growth businesses. Since its founding, Long Ridge has sponsored many successful growth companies in the financial and business technology sectors, providing founders and management teams with partnership, strategic resources, and capital to drive profitable expansion. Long Ridge manages over $1.75 billion of committed capital. For more information on Long Ridge Equity Partners, please visit www.long-ridge.com.

SOURCE OnCorps AI